The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

Forget about basic stand-on devices that measure weight and basic body composition stats; this advanced foot-to-hand smart scale can do that and so much more.

Feb 17 (Reuters) - Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy reduced the severity of symptoms in a late-stage study, sending its shares up nearly 30%. The ...

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

Hong Kong’s IPO boom is redrawing the legal hierarchy, with Chinese firms surging in volume and foreign firms still retaining the most complex mandates. The divide underscores a market increasingly ...

New York’s RAISE Act was significantly reworked in January 2026, replacing proposed deployment bans with a more targeted ...

When thinking about the American people, columnist David Brooks is a glass-half-full kind of guy.